2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2015

9:00AM-11:00AM: Abstract Number: 1967

Deregulation of Interleukin-22 Pathway in Giant Cell Arteritis

Vasculitis Poster II

9:00AM-11:00AM: Abstract Number: 1587

Deriving a Comorbidity Index Form the Meddra Classification: Performance of Rheumatic Disease Comorbidity Index, Charlson-Deyo Index and Functional Comorbidity Index Among Patients with RA in NOR-DMARD Cohort

Rheumatoid Arthritis - Clinical Aspects Poster II

9:00AM-11:00AM: Abstract Number: 1442

Descriptive Characteristics of Patients Prescribed Opioids for the Treatment of Chronic Pain

Pain: Basic and Clinical Aspects Poster

9:00AM-11:00AM: Abstract Number: 1198

Design and Implementation of a Patient-Centered Navigator Program to Improve Adherence to Disease-Modifying Antirheumatic Drugs

Education Poster (ARHP): Education/Community Programs

9:00AM-11:00AM: Abstract Number: 1315

Detecting Subtle Changes in Bone Structure Following Three-Month Anti-TNF Theraphy Using High-Resolution Peripheral Quantitative Computed Tomography

Imaging of Rheumatic Diseases Poster II: X-ray, MRI, PET and CT

9:00AM-11:00AM: Abstract Number: 1358

Detection of a Unique Viral Infection in Salivary Glands of Sjögren’s Syndrome Patients and Viral-Mediated Recapitulation of Disease in Vivo

Infection-related Rheumatic Disease: Poster Session

9:00AM-11:00AM: Abstract Number: 1525

Detection of Previous Tuberculosis Infections in Japanese Rheumatoid Arthritis Patients: Comparison of Two Interferon-G Releasing Assays and the Impact of CD4-Positive Lymphocytes

Rheumatoid Arthritis - Clinical Aspects Poster II

9:00AM-11:00AM: Abstract Number: 1190

Developing an Introductory Musculoskeletal Ultrasound Curriculum for Rheumatology Fellows

Education Poster I

9:00AM-11:00AM: Abstract Number: 1917

Developing and Validating a Serum Biomarker for the Extent of Skin Disease in Patients with Diffuse Cutaneous Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics Poster I

9:00AM-11:00AM: Abstract Number: 1484

Development and Validation of Juvenile Autoinflammatory Disease Multidimensional Assessment Report (JAIMAR)

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters. Juvenile Arthritis and Miscellaneous Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1712

Development of a Novel SI Joint CT Score for Diagnosis of Axial Spondylitis

Spondylarthropathies and Psoriatic Arthritis - Comorbidities and Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1635

Development of New Bioassay System Measuring Inhibitory Strength of IL-6/STAT3 Signal Under Tocilizumab Treatment in Rheumatoid Arthritis Patients

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster II

9:00AM-11:00AM: Abstract Number: 1402

Development of Systemic Juvenile Idiopathic Arthritis Manifestations Following Remission of Hemophagocytic Lymphohistiocytosis

Miscellaneous Rheumatic and Inflammatory Diseases Poster Session II

9:00AM-11:00AM: Abstract Number: 1904

Development of the Mawdsley Calcinosis Questionnaire (MCQ) Version 1 – a Patient-Reported Outcome Measure (PROM) for Systemic Sclerosis Related Calcinosis (SSc-Ca)

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster II

9:00AM-11:00AM: Abstract Number: 1596

Diagnosis of Carotid Plaque By 4 Cardiovascular Risk Scores in Rheumatoid Arthritis

Rheumatoid Arthritis - Clinical Aspects Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].